This article is a correction to:
Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials
An Wang1,†
Mengqi Chen1,†
Qi Zhuang1Lihua Guan2
Weiping Xie3
Lan Wang4
Wei Huang5Zhaozhong Cheng6
Shiyong Yu7Hongmei Zhou8Jieyan Shen1*
- 1Department of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- 2Department of Cardiology, Shanghai Institute of Cardiovascular Disease, Zhongshan Hospital, Fudan University, Shanghai, China
- 3Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
- 4Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
- 5Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
- 6Respiratory Department, The Affiliated Hospital of Qingdao University, Qingdao, China
- 7Department of Cardiology, The Second Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing, China
- 8Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, China
A Corrigendum on
By Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, Huang W, Cheng Z, Yu S, Zhou H, Shen J. (2023). Front Cardiovasc Med. 10:1142721. doi: 10.3389/fcvm.2023.1142721
Incorrect Funding
In the published article, there was an error in the Funding statement.
There was an error in specifying the grant number of National Natural Science Foundation of China (CN) in the Funding section of the paper. The correct grant number is [81970047] and [82270050], but it was mistakenly written as [81800047].
The original text was: This work was supported by the National Natural Science Foundation of China (CN) (81800047) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).
The correct Funding statement appears below.
Funding
This work was supported by the National Natural Science Foundation of China (CN) (81970047, 82270050) and the Clinical Research Innovation and Incubation Foundation of Renji Hospital, Shanghai Jiao Tong University School of Medicine (PYII20-13).
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pulmonary arterial hypertension, time to clinical improvement, efficacy, risk stratification, 6-min walk distance
Citation: Wang A, Chen M, Zhuang Q, Guan L, Xie W, Wang L, Huang W, Cheng Z, Yu S, Zhou H and Shen J (2024) Corrigendum: Time to clinical improvement: an appropriate surrogate endpoint for pulmonary arterial hypertension medication trials. Front. Cardiovasc. Med. 11:1371699. doi: 10.3389/fcvm.2024.1371699
Received: 16 January 2024; Accepted: 18 January 2024;
Published: 21 February 2024.
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
© 2024 Wang, Chen, Zhuang, Guan, Xie, Wang, Huang, Cheng, Yu, Zhou and Shen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jieyan Shen shenjy_66@163.com
†These authors have contributed equally to this work